ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in…
Month: April 2023
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in…
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
Data presented at AACR Annual Meeting support IMM-1-104’s potential to address a broad population of…
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
Data presented at AACR Annual Meeting support IMM-1-104’s potential to address a broad population of…
Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies
Preclinical data suggests that sudocetaxel zendusortide can induce immune cell infiltration in “cold” tumors and…
Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies
Preclinical data suggests that sudocetaxel zendusortide can induce immune cell infiltration in “cold” tumors and…
Ashvattha Therapeutics Presented Promising Preclinical Data on Novel Macrophage Switching Nanomedicine D-4559 at AACR Annual Meeting
Data demonstrated D-4559 switches tumor associated macrophages from an M2 to M1 pro-inflammatory phenotype leading…
Ashvattha Therapeutics Presented Promising Preclinical Data on Novel Macrophage Switching Nanomedicine D-4559 at AACR Annual Meeting
Data demonstrated D-4559 switches tumor associated macrophages from an M2 to M1 pro-inflammatory phenotype leading…
Notable Labs Presents Clinical Platform Validation Data at the 2023 American Association for Cancer Research Annual Meeting
– 100% accuracy predicting clinical responders with Notable’s PPMP with enhanced machine learning – – Fourth clinical…
Notable Labs Presents Clinical Platform Validation Data at the 2023 American Association for Cancer Research Annual Meeting
– 100% accuracy predicting clinical responders with Notable’s PPMP with enhanced machine learning – – Fourth clinical…
invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing…
invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing…
Y-mAbs Announces Presentation of Naxitamab data at AACR
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)…
Y-mAbs Announces Presentation of Naxitamab data at AACR
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)…
Elevar Therapeutics Presents AACR 2023 Poster Demonstrating Rivoceranib as Most Selective VEGFR-2 Inhibitor When Compared to Other TKIs With Known Activity Against VEGFR-2
ORLANDO, Fla., April 18, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a fully integrated biopharmaceutical…
Elevar Therapeutics Presents AACR 2023 Poster Demonstrating Rivoceranib as Most Selective VEGFR-2 Inhibitor When Compared to Other TKIs With Known Activity Against VEGFR-2
ORLANDO, Fla., April 18, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a fully integrated biopharmaceutical…
Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL
Qualigen Therapeutics, Inc. Abstract #4981 Qualigen Therapeutics, Inc. Abstract #6240 CARLSBAD, Calif., April 18, 2023…
Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL
Qualigen Therapeutics, Inc. Abstract #4981 Qualigen Therapeutics, Inc. Abstract #6240 CARLSBAD, Calif., April 18, 2023…
Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
The iLSTA Trial is the first study combining LSTA1 with standard-of-care chemotherapy and immunotherapy WARPNINE…
Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
The iLSTA Trial is the first study combining LSTA1 with standard-of-care chemotherapy and immunotherapy WARPNINE…